Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

, 73 of the approximately 100 clinical sites in the SPEAR study are active, and the balance of sites is to be opened as planned. Based on recent enrollment data, Poniard estimates that it will complete enrollment in 3Q 2008.

Poniard continues to anticipate filing a New Drug Application with the FDA in 2009. The Company received fast track designation from the FDA for picoplatin for the second-line treatment of refractory or resistant SCLC, allowing a rolling NDA submission.

"We are encouraged by the enrollment pace at our sites that have been open for three months or more, because these are enrolling patients better than at the anticipated rate," added Dr. McMahon. "Based on our prior trial in SCLC, and our experience at many of our active SPEAR sites, we anticipate an acceleration of enrollment as more sites are open longer and new sites are opened. In addition to patients that have already enrolled, we are following approximately 200 additional SCLC patients currently receiving first-line treatment who may be eligible to participate in the SPEAR trial."

Phase 2 CRC Trial:

Poniard is also evaluating intravenous picoplatin as a replacement for oxaliplatin in an ongoing Phase 2 trial for the first-line treatment of metastatic CRC with picoplatin in combination with 5-fluorouracil and leucovorin, or FOLPI, compared to the standard-of-care FOLFOX regimen, including oxaliplatin, in a 100-patient randomized trial.

The Company has opened 18 of the planned 23 clinical sites and is enrolling patients in this randomized trial, which is evaluating picoplatin as a first-line agent in CRC. The Company is treating patients in the trial and expects to fully enroll the trial in the first half of 2008. Poniard expects to present clinical data from the Phase 1 and Phase 2 CRC trials at scientific meetings throughout 2008.

Phase 2 HRPC Trial:

Intravenous picoplatin also is under evaluation in an ongoing Phase 2 trial for the treatment
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... --  Life Technologies Corporation (NASDAQ: LIFE ... and 3500xL Dx Genetic Analyzers have been approved by ... Mexico for diagnostic use.  The ... to serve the clinical end market in ... -based solutions.  The Applied Biosystems™ 3500 ...
(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4
(Date:5/21/2013)... It took Willie Benitez, a heroin ... sixth time on a fifteen year sentence, six months ... to trust him enough to allow Willie to start ... “NarcoNon” Willie intended to name his “drug rehabilitation foundation,” ... and did start up that class. , Early ...
(Date:5/21/2013)... Leading New Jersey real estate agent, ... One of her favorite aspects of walkable places is ... light of the current childhood obesity epidemic that plagues ... walkable living. , A New York Academy of Sciences ... neighborhoods as a key combatant to obesity. The same ...
(Date:5/21/2013)... 2013 Dr. James C. Wittig, Chief ... the Sarcoma Division of the John Theurer Cancer Center ... been named one of the top 13 Orthopedic Oncologists ... Dr. Wittig is one of approximately 125 surgeons in ... created by surveying thought leaders in the field of ...
(Date:5/21/2013)... The Michigan Lupus Foundation will be holding a ... 11th. , Meeting Details: , Tuesday, June 11th , ... Room 5 (Lower Level),     1375 North Main Street,     Lapeer, ... people with lupus and their family and friends to ... better understanding of this disease and how to fight ...
(Date:5/21/2013)... 21, 2013 Joe Vitale, a positive thinking ... adapter of the Fisker electric car. After a year and ... the car company went bankrupt, the bestselling author turned grumpy ... , "It's a gas guzzler's anthem," says Vitale, 59, who ... "Sun Will Rise." , Owning this Fisker was a ...
Breaking Medicine News(10 mins):Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 2Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 3Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 4Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 5Health News:New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity 2Health News:New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity 3Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:Upset Fisker Owner Records Gas Guzzler Anthem 2
... someday help control anxiety, experts say, , , FRIDAY, May 15 ... anxiety isn,t something associated with heights, a job interview or ... state of worry and tension that affects twice as many ... slowly eroding their quality of life. , But a new ...
... ORLANDO A pill used for nerve pain offers women ... 45th Annual Meeting of the American Society of Clinical ... hot flash severity and frequency about 20 percent more than ... the same benefit as gabapentin, an older, related drug, as ...
... in GI and Endoscopy Nursing at SGNA 36th Annual ... Nurses and Associates, Inc. (SGNA) is proud to honor ... awards that recognize their dedication to the field and ... distinguished awards represent the best in GI and endoscopy ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... Palatin reported net income of $0.1 million, or $0.00 per basic ... to a net loss of $5.1 million, or $0.06 per basic ... revenues in the quarter ended March 31, 2009 were $5.2 million, ...
... 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality, pharmaceutical grade,glucose products in China, ... of fiscal 2009 ended March 31, 2009. , ... has impacted our operations thus far in,fiscal year ...
... Dr. Bruno E. Gerber is recognized in ... is a Consultant Orthopedic Surgeon with a special ... of the lower limbs. He also is employed ... development project regarding innovative orthopedic laser treatment.Dr. Gerber ...
Cached Medicine News:Health News:Fear Response May Stem From Protein in Brain 2Health News:Mayo Clinic researchers say agent provides treatment option for women with hot flashes 2Health News:Mayo Clinic researchers say agent provides treatment option for women with hot flashes 3Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 2Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 3Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 6Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 2Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 3Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 4Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 5Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 6Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 7Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 8Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 9Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 10Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 11Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 12Health News:Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional 2
... The TOPCON OM-4 Ophthalmometer ... compactly designed and easy ... providing precise objective measurements ... of curvature plus accurate ...
... Based on the latest digital chip ... FA/Color System from Topcon features 3,072 x ... range for each color channel! The system ... also features real-time image acquisition, which facilitates ...
... Set offers a maximum selection ... corrected curve additive design that ... spacing between combined lenses. This ... be read directly from the ...
... power table has everything that you need ... new AIT-15 offers 20 mm of additional ... and locking castors to secure the table. ... for most any application. Use a double ...
Medicine Products: